ERBB2 and breast cancer: Patients with estrogen-dependent (ER+) or human epidermal growth factor receptor 2 (HER2) oncoprotein–expressing breast cancers in particular have benefited from treatment de-escalation from chemotherapy to well-tolerated targeted therapy and hormonal prophylaxis (62, 75).